Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Non Small Cell Lung Cancer|Breast Cancer
Interventions: DRUG: YPEG-rhG-CSF, 20μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|DRUG: YPEG-rhG-CSF, 30μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|DRUG: YPEG-rhG-CSF, 45μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|DRUG: PEG-rhG-CSF, 100μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle
Sponsor: Xiamen Amoytop Biotech Co., Ltd.